CEO change for Meda AB
After 14 years as CEO at Meda, Anders Lönner has decided to step down from the position. The Board of Directors has named Dr. Jörg-Thomas Dierks as the new CEO. Dierks has been the Chief Operating Officer at Meda since 2005. Dierks is 53 years old and has an education as a medical doctor. He has long experience in the pharmaceutical industry at NovoNordisk and Viatris before coming to Meda.
”Every journey has to end. I’m very glad to be placing the organization in the hands of Jörg-Thomas, who is highly competent, experienced, and has strong organizational support,” says Anders Lönner. “Meda has a strong portfolio of new products, and its focus now will be to optimize the marketing of these products as opposed to acquisition of new products. As a result, this is a good time to make this transition. As for me, I will be spending my time with own and associated companies in the pharmaceutical area.”
“Anders Lönner has done outstanding work during his last 14 years as CEO of Meda,” says Bert Åke Eriksson, Chairman of Meda’s Board. “With his unique business skills, he has transformed Meda from a small, insignificant distributor in Scandinavia to a major global pharmaceutical company. The Board wishes to express its sincere thanks to Anders Lönner.”
For further inquiries, please contact:
Anders Lönner Phone: +46 8-630 1972
MEDA AB (publ) is a leading international specialty pharma company. Meda’s products are sold in more than 120 countries worldwide and the company is represented by its own organizations in over 55 countries. The Meda share is listed under Large Cap on the Nasdaq OMX Nordic Stock Exchange in Stockholm. Find out more, visit www.meda.se.
This press release is not an offer to sell or a solicitation to buy shares in Meda. This press release also contains certain forward-looking statements with respect to certain future events and Meda’s potential financial performance. These forward-looking statements can be identified by the fact that they do not relate only to historical or current facts, and may sometimes include words such as “may”, “will”, “seek”, “anticipate”, “expect”, “estimate”, “intend”, “plan”, “forecast”, “believe” or other words of similar meaning. These forward looking statements reflect the current expectations on future events of the management at the time such statements are made, but are made subject to a number of risks and uncertainties. In the event such risks or uncertainties materialize, Meda’s results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with the inherent uncertainty of pharmaceutical research and product development, manufacturing and commercialization, the impact of competitive products, patents, legal challenges, government regulation and approval, Meda’s ability to secure new products for commercialization and/or development and other risks and uncertainties detailed from time to time in Meda AB’s interim or annual reports, prospectuses or press releases. Listeners and readers are cautioned that no forward-looking statement is a guarantee of future performance and that actual result could differ materially from those contained in the forward-looking statements. Meda does not intend, nor undertakes, to update any such forward looking statements.